Latest Advances in CGM Technology: A 5-question Quiz

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

News

Article

Continous glucose monitors (CGMs) received a flurry of US Food and Drug Administration (FDA) appprovals in 2018. Since then, the FDA-approved CGMs have benefited from a variety of enhanced features, new applications, and new approvals that promise to further advance the management of diabetes and thus the functioning and quality of life of patients with diabetes.

Take the 5-question quiz below to see what you know about key original CGM approvals and features and the innovations and advances that have been approved since.

1. Which of the following was the first FDA-approved CGM system to include a fully implantable sensor to detect glucose?

Related Content

January 17th 2025

Obesity & Type 2 Diabetes: An Expert Discussion

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

June 30th 2023

CAH Update: High-Level Examination of Condition Published in Expert Review of Endocrinology & Metabolism, Neurocrine Announces

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

January 16th 2025

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

"Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms," offers an in-depth look at the disorder and promising therapies.

July 22nd 2022

Atumelnant Demonstrates Rapid and Sustained Biomarker Reduction in Phase 2 Trial in Adults with Congenital Adrenal Hyperplasia

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

January 10th 2025

Elinzanetant Meets All Endpoints in Phase 3 Study of VMS Caused by Adjuvant Endocrine Therapy for Breast Cancer

Atumelnant treatment resulted in statistically significant reductions in serum androstenedione and 17-OHP as well as notable improvements in CAH symptoms.

January 9th 2025

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

Elinzanetant produced a statistically significant reduction in frequency of treatment-related vasomotor symptoms as early as week 1 and in severity at weeks 4 and 12.

Related Content

January 17th 2025

Obesity & Type 2 Diabetes: An Expert Discussion

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

June 30th 2023

CAH Update: High-Level Examination of Condition Published in Expert Review of Endocrinology & Metabolism, Neurocrine Announces

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

January 16th 2025

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

"Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms," offers an in-depth look at the disorder and promising therapies.

July 22nd 2022

Atumelnant Demonstrates Rapid and Sustained Biomarker Reduction in Phase 2 Trial in Adults with Congenital Adrenal Hyperplasia

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

January 10th 2025

Elinzanetant Meets All Endpoints in Phase 3 Study of VMS Caused by Adjuvant Endocrine Therapy for Breast Cancer

Atumelnant treatment resulted in statistically significant reductions in serum androstenedione and 17-OHP as well as notable improvements in CAH symptoms.

January 9th 2025